[Abstract]2022 Apr;42(4):694-705
At the EASL Congress 2024, Eli Lilly and Company presented positive results from the Phase II clinical trial, SYNERGY-NASH, of their tirzepatide for treating patients with biopsy-proven MASH with stage 2 or 3 fibrosis
We would like to highlight that, while eliminating the possibility of hospitals achieving a 5-star rating despite being in the lowest quartile of Safety of Care is part of the intent of this update, it is not the sole purpose
doi:10.3390/biomedicines12102205 115
Manufacturer savings programs from Novo Nordisk and Eli Lilly reduce monthly costs to as little as $25 for eligible patients
When a solution arrives ready to use, its concentration has already been confirmed, and the formulation follows a standardized protocol